Pain Management in Autoimmune Diseases

Initial Therapy

For mild to moderate pain in autoimmune conditions, the American College of Rheumatology recommends using NSAIDs as first-line therapy, with the goal of minimizing cardiovascular, renal, and gastrointestinal risks 1
The initial dose of NSAIDs, such as naproxen, can be 325-500 mg twice daily, with the lowest effective dose used for the shortest duration to minimize risks 1

For moderate to severe inflammatory pain or disease flares, prednisone 10-20 mg/day is recommended, with higher doses (40 mg/day or equivalent) for severe pain limiting self-care activities 1, 2
The American College of Rheumatology suggests tapering corticosteroids after 3-4 weeks if symptoms improve, and considering early referral to rheumatology for steroid-sparing strategies 1, 2

DMARDs are essential for long-term pain control by addressing underlying inflammation, and should be considered when unable to lower corticosteroid dose to <10 mg/day after 3 months 1
Options for DMARDs include methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine, with the goal of reducing inflammation and preventing disease progression 1

For refractory pain despite conventional DMARDs, biologic agents such as TNF-α inhibitors (adalimumab, etanercept, infliximab) and IL-6 receptor antagonists (tocilizumab) may be considered 1, 2
The American College of Rheumatology recommends considering biologic agents, such as rituximab (B-cell depleting therapy) and JAK inhibitors, for patients with refractory pain despite conventional DMARDs 1, 3

For pain with neuropathic features or central sensitization, gabapentin (300-3600 mg/day in divided doses) or pregabalin (150-600 mg/day) may be considered, with the goal of reducing pain and improving function 4
The American Academy of Neurology recommends starting at a low dose and titrating gradually, with adjustments made for renal impairment 4

For localized joint or muscle pain, topical NSAIDs, capsaicin cream (0.025-0.075%), and lidocaine patches may be considered, with the goal of reducing pain and improving function 5
The American College of Rheumatology recommends considering compounded amitriptyline 1-2% with ketamine 0.5-5% for localized pain, with the goal of reducing pain and improving function 5

For moderate to severe pain, a multimodal approach may be considered, including optimizing NSAIDs, adding low-dose corticosteroids, and considering adjunctive therapy (gabapentin/pregabalin or antidepressants) 1, 2
The American College of Rheumatology recommends considering referral to rheumatology and optimizing DMARDs to address underlying inflammation, with the goal of reducing pain and improving function 1, 2

The American College of Rheumatology recommends physical therapy focusing on core strengthening, cognitive behavioral therapy (CBT) for chronic pain management, weight management for arthritis, and sleep interventions to address pain-related sleep disturbances 4, 6
Regular assessment of pain control and function, monitoring for medication side effects, and screening for depression and anxiety are also recommended, with adjustments made to therapy based on response and disease activity 4, 6

The American College of Rheumatology recommends avoiding long-term NSAID use due to cardiovascular, renal, and gastrointestinal risks, and using corticosteroids at the lowest effective dose for the shortest duration 4
Opioids should not be first-line for chronic autoimmune pain due to risks of addiction and other adverse effects, and monitoring for steroid-induced complications with prolonged use is recommended 4